The FDA has approved the first drug specifically developed to treat postpartum depression; a new study links frequent and high-potency marijuana use to psychosis; and the Mississippi Senate has passed its heartbeat abortion ban.
The FDA approved Sage Therapeutics’ brexanolone (Zulresso), the first drug specifically developed to treat postpartum depression, reported The Associated Press. The intravenous drug, administered over 2.5 days, comes with an estimated price tag of $34,000 without insurance. A study assessing the drug found that when new mothers with moderate to severe depression took brexanolone, half stopped feeling depressed after 2.5 days, which was double the rate seen with those taking placebo.
As states around the country continue to take steps toward legalizing marijuana, a new study from The Lancet Psychiatry is warning of a health risk associated with frequent use: psychosis. According to the study, high frequency of daily marijuana use and high-potency marijuana increases the risk of a psychotic disorder, with daily marijuana users being 3.2 times more likely to have a psychotic disorder than never users and high potency users being 1.6 times more likely.
The Mississippi Senate passed its heartbeat abortion ban, which could bar abortion as early as 6 weeks into a women’s pregnancy. Fifteen Democrats voted against the bill. Governor Phil Bryant, R-Mississippi, has signaled that he will sign the legislation. If signed, the state will have the most restrictive abortion policy in the United States, although other states are debating similar legislation, reported Mississippi Today.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Patient Navigation in Oncology at Heart of Priority Health White House Visit
April 24th 2024On March 27, Priority Health's president and CEO, Praveen Thadani participated in a discussion on how to expand and optimize patient navigation services in oncology care, as part of the Cancer Moonshot initiative.
Read More